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Introduction
Reliable methods of noninvasive prenatal diagnosis
have long been sought in perinatal medicine (Table
1). Current means of prenatal diagnosis, such as amnio-
centesis and chorionic villus sampling, carry small but
significant risks of miscarriage, although these methods
are highly accurate. Only a small subgroup of pregnant
women, generally 35 years or older, are offered these in-
vasive methods. However, screening based on maternal
age alone misses a large number of cases, since 80% of
infants with trisomy 21 are born to women 35 years of
age or younger [19]. Thus, since the late 1980s, alter-
native noninvasive methods of screening, including serum
analysis and ultrasound evaluation, have been explored
to improve the efficiency of screening [20]. Although
these noninvasive methods can detect approximately
85% of cases of fetal aneuploidy with a false-positive
rate of 5%, they do not provide a definitive diagnosis;
rather, they estimate a woman’s adjusted (or posterior)
risk for various chromosomal aneuploidies. In the de-
veloped world, the percentage of pregnant women 35
years or older has increased steadily since the 1980s.
Therefore, the percentage of Down syndrome preg-
nancies involving women of advanced maternal age
has increased from approximately 30% to 40% [21].
These women and their partners generally have only
one or two children and therefore many are reluctant to
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be exposed to the risk of an invasive prenatal diagnostic
test. The development of newer noninvasive methods by
which to assess fetal genetic and/or chromosomal ab-
normalities is thus expected to improve accuracy of de-
tection.
Recently, two methods of noninvasive prenatal
diagnosis have been subject to investigation: fetal cells
and cell-free DNA circulating within maternal blood
(plasma or serum). The use of cell-free fetal DNA was
discussed in a previous review published in this jour-
nal [22]. The present review focuses on the use of fe-
tal cells within the maternal circulation for prenatal
diagnosis.
Fetal Cells in the Maternal Circulation
Trophoblasts
It has long been known that trophoblasts circulate in
maternal blood. At the turn of the 19th century, German
Table 1. History of fetal cell discovery in maternal blood
Year Author Target cells
1863 Schmorl [1] Trophoblasts
1959 Douglas et al [2] Trophoblasts
1969 Walknowska et al [3] WBCs
1972 Schroder and De la WBCs
   Chapelle [4]
1984 Covone et al [5] Trophoblasts
1988 Covone et al [6] Trophoblasts
1989 Lo et al [7] Whole blood
1990 Mueller et al [8] Trophoblasts
1990 Bianchi et al [9] NRBCs
1991 Price et al [10] NRBCs
1992 Bianchi et al [11] NRBCs
1992 Cacheux et al [12 ] Trophoblasts
1993 Ganshirt-Ahlert NRBCs
   et al [13]
1993 Hamada et al [14] Mononuclear
   cells
1995 Takabayashi et al [15] NRBCs
1996 Sekizawa et al [16] NRBCs
1995– NIFTY study [17] NRBCs
   1999
2002 Kitagawa et al [18] NRBCs
WBC = white blood cell; FISH = fluorescence in situ hybridization; PCR = polymerase chain reaction; NRBC = nucleated erythrocyte; FACS = fluorescence-
activated cell sorting; TfR = transferrin receptor; MACS = magnetic-activated cell sorting.
Content
Trophoblasts observed in pulmonary vessels of
women dead due to preeclampsia
Trophoblasts detected in maternal blood
WBCs with XY karyotype detected in cultured
blood from male-bearing pregnant women
Fetal WBCs detected by Y-chromatin in the
blood of pregnant women
Trophoblast detection by flow cytometry with
H315 antibody
Trophoblast detection and analysis through
FISH
Fetal DNA detected in whole blood samples
from male-bearing pregnant women
Trophoblast enrichment and analysis by PCR
NRBC enrichment by FACS with transferrin
receptor antibody and confirmed Y-specific
sequence
After FACS separation, fetal trisomy 21
diagnosed by FISH analysis
After FACS separation by transferrin receptor,
fetal trisomy 21 diagnosed by FISH analysis
Separation of trophoblasts by immunobeads
and diagnosis of fetal aneuploidy 47,XYY by
FISH analysis
NRBC enrichment by MACS and diagnosis of
trisomy 21 or 18 cells
FISH applied to mononuclear cells confirmed
the number of fetal cells in maternal blood
(early gestation: 1/100,000 mononuclear
cells)
NRBCs separated by double density gradients.
After confirmation of NRBCs, cell individually
micromanipulated.
NRBCs isolated by Takabayashi method and cell
was individually analyzed by PCR for
Duchenne muscular dystrophy
Evaluation of the prenatal diagnosis accuracy
through NRBCs in maternal blood
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pathologist Schmorl demonstrated trophoblasts in
the lungs of women who died from eclampsia [1]. In
1959, Douglas et al detected trophoblasts in maternal
blood using light microscopy [2]. However, the limited
number of trophoblasts normally present in maternal
blood led to difficulty reproducing their findings. It is
difficult to isolate trophoblasts since they are large
multinucleated cells that become trapped in the lungs
and are rapidly cleared from the maternal circulation
[23], even in women with hypertension in pregnancy,
from whom trophoblasts have been recovered from
the uterine vein, inferior vena cava [24], and peripheral
circulation [5]. In addition, trophoblast trafficking
seems not to be a phenomenon common to all preg-
nancies [25]. Enrichment of these cells is difficult due
to a lack of specific antibodies [26,6]. Furthermore, it
is known that 1% of placental karyotype differs from
that of the fetus due to confined placental mosaicism
[27,28]. This also restricts the use of trophoblasts in
maternal blood as a tool for genetic diagnosis. However,
despite these obstacles, some diagnostic success has
been achieved through detection of Y-chromosome
sequences by polymerase chain reaction (PCR) amplifi-
cation and fluorescence in situ hybridization (FISH)
techniques using trophoblasts from maternal blood
[8,29,30]. Hawes et al have also accurately detected a
fetal `-globin mutation in trophoblasts from maternal
blood [29].
Leukocytes
Through successful enrichment of leukocytes from
the maternal circulation, it has been demonstrated that
fetal leukocytes traverse the placenta. This has made
noninvasive prenatal diagnosis possible. Although
Schmorl discovered the presence of trophoblasts in
the maternal circulation almost a century ago, the use
of fetal cells for prenatal diagnosis was not considered
feasible until 1969. At this time, Walknoska et al observed
cells with a 46,XY karyotype in cultured lymphocytes
from 21 pregnant women, 19 of whom subsequently
delivered male infants [3]. This finding was later con-
firmed by other investigators in the early 1970s, who
also demonstrated Y-chromatin within cells in the
maternal circulation of women carrying male fetuses
[31,4,32–36]. However, hundreds of maternal cells
need to be analyzed in order to document the presence
of just a few fetal cells in the maternal circulation, a
labor-intensive process. Thus, these studies used
methods to enrich fetal cells for detection, including a
nylon wool column and selective cell culturing [37,38].
Herzenberg’ group were the first to use fluorescence-
activated cell sorting (FACS) to successfully enrich fetal
leukocytes from the maternal circulation [39,40]. They
showed a significant correlation between a male fetus
at birth and human leukocyte antigen HLA-A2 with
detection of a quinacrine-positive Y body in flow-sorted
cells. This method, which requires HLA-typing of the
father, was validated in a subsequent study using PCR
amplification of Y chromosome-specific sequences
after flow-sorting based on paternal HLA polymorphisms
[25] However, other investigators have had limited
success using this method, even following selection
based on several HLA differences using monoclonal
antibodies. One study found only 18 HLA-informative
couples out of 78 screened [41].
All observations to date suggest persistence of
fetal cells in maternal blood. Early interest in fetal
leukocytes for prenatal diagnosis was based on their
ability to proliferate in vitro, suggesting that they might
also proliferate in vivo in maternal organs. That meant
that this approach could theoretically lead to mis-
diagnosis in multigravida. An early study by Schroder
et al determined that fetal leukocytes can still be de-
tected in the maternal circulation up to 1 year after
birth [42]. This study used mitogen stimulation of
leukocytes in order to detect Y-chromatin in a woman
who had previously born a son. This has been confirmed
by others, in some instances up to 5 years post-partum
[43–45]. Moreover, Bianchi et al used FACS enrich-
ment of  T and B lymphocytes to identify the presence
of fetal progenitor cells (CD34+, 38+) in the maternal
circulation 27 years post-partum [46]. In another study,
T lymphocytes (CD3+, 4+, 5+) were found to persist,
for as many as 6 years in one instance, after birth. These
studies indicate that cell types with a short life-span
should be used for prenatal diagnosis.
Fetal erythrocytes/nucleated red blood cells
In 1976, Kleihauer et al demonstrated the presence
of immature erythrocytes circulating in maternal blood
using a new staining method [47]. In 1964, Clayton et
al observed nucleated erythrocytes (NRBCs) more
frequently under certain circumstances, such as rhesus
incompatibility, or following amniocentesis and ter-
mination [48]. NRBCs are one of the first hemopoietic
cell lines produced during fetal development. They are
abundant in the fetal circulation during early pregnancy
[49]. When blood pools at the interface between fetal
and maternal tissue, transfer of erythrocytes, including
NRBCs, into the maternal circulation predominates
over that of other cell types, including leukocytes and
trophoblasts. NRBCs are mononuclear and relatively
well differentiated. They also have a short life-span com-
pared to fetal lymphocytes given their limited prolifer-
ative capacity [50], making them unlikely to persist
throughout pregnancy. These characteristics make
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NRBCs particularly suitable for noninvasive prenatal
diagnostic testing.
In 1990, Bianchi et al discovered a way to enrich
NRBCs containing fetal DNA for FACS using a mono-
clonal antibody against the transferrin receptor (CD71),
which is highly expressed on erythoblasts [9]. The abi-
lity to do so has since been confirmed by other investi-
gators using a variety of monoclonal antibodies and cell
enrichment techniques [10,51–53]. One such method
is magnetic cell sorting (MACS) using an antibody to
CD71 [54]. Ganshirt-Ahlert et al have used MACS fol-
lowing NRBC enrichment to correctly identify fetal
aneuploidy [13,24] These successful attempts at NRBC
enrichment and fetal determination demonstrate the
potential of using NRBCs for noninvasive prenatal
diagnosis.
However, the isolation of fetal cells from the mater-
nal circulation presents considerable challenges, given
their limited numbers. Fetal cells are estimated to range
from 1 in 105 to 1 in 109 cells in maternal blood [10,55].
Hamada et al used FISH on mononuclear cells isolated
by density gradient separation from maternal blood to
find Y chromosome-bearing cells [14] They needed to
screen as many as 144,000 nuclei to find a single fetal
cell containing DNA that hybridized to the Y chromo-
some. An increased frequency of fetal cell isolation
with gestational age was observed, from less than 1 in
105 during the first trimester to 1 in 104 at term. Bianchi
et al examined the number of fetal-cell DNA equivalents
present in maternal blood by PCR amplification of a Y
chromosome-specific sequence and found approxi-
mately one fetal cell per 1 mL of maternal blood [56].
Thus, although the presence of fetal NRBCs in mater-
nal blood is well established, and they are currently
considered the best target for noninvasive prenatal
diagnosis, their detection remains problematic.
Undoubtedly, some NRBCs, even after fetal cell
enrichment, are of maternal origin [49,57–59]. De Graff
et al used fetal hemoglobin to differentiate maternal
from fetal NRBCs, but 20% of all fetal hemoglobin-
positive NRBCs were still of maternal origin [60].
Recently, Troeger et al used single-cell PCR analysis on
single micromanipulated NRBCs identified by May-
Grunwald Giemsa staining to demonstrate that almost
half of NRBCs in maternal blood are of fetal origin
[61]. These findings suggest that the origin of each
cell must be confirmed for reliable clinical use when
performing noninvasive prenatal diagnosis through
analysis of cells recovered from maternal blood.
Another approach is to culture NRBCs. If selective
induction of NRBC proliferation occurs in vitro, fetal
genetic material can be amplified for noninvasive pre-
natal diagnosis. Lo et al were the first to culture mono-
nuclear cells and to isolate fetal erythroid progenitors
from the peripheral blood of pregnant women [62].
Subsequently, other investigators have successfully
cultured colony-forming units, as well as erythroid and
mature burst-forming units and erythroid colonies, from
fetal hemopoietic progenitors enriched from maternal
blood [63]. However, these results have not been
replicated consistently, and thus far selective amplifi-
cation of fetal over maternal hemopoietic progenitors
has not been successful [64,65].
Physiologic Variation in the
Maternal Circulation
Data indicating the timing of fetal cell trafficking
into the maternal circulation exists. In mice, fetal cell
migration is a rare event [66]. In general, it is thought
that the proportion of NRBCs to non-nucleated ery-
throcytes diminishes in fetal blood as gestation pro-
gresses in humans. In accordance with placental growth,
the interface between fetal and maternal tissue ex-
pands, such that more fetal cells may traverse the
placental barrier in the early stages of gestation. In a
study of two pregnant women bearing male fetuses
following in vitro fertilization, Y chromosome-specific
DNA was detected as early as 33 and 40 days gesta-
tion [67,68]. PCR amplification of a Y chromosome-
specific sequence has been achieved in maternal blood
at between 6 and 12 weeks in two separate studies
[14,69]. Other studies using flow-sorted NRBCs have
demonstrated reliable detection of fetal DNA at less
than 16 weeks of gestation [70].
It has been reported that more fetal cells are re-
covered when the fetus is aneuploid [56,71]. This
might be associated with the ultrastructure of the
placenta in pregnancies affected by aneuploidy [72,
73]. It might also be associated with erythrocyte size,
which differs from that in cytogenetically normal in-
dividuals of the same gestational age [74]. Aneuploid
fetal cells express CD71 [75] or FB3-2 and H3-3 [76]
antigens. Simpson and Elias demonstrated that, on
average, 19.6% (074%) of enriched cells from mater-
nal samples were trisomic fetal cells, using FISH ana-
lysis with chromosome-specific probes [77]. Using the
same method, Ganshirt-Ahlert et al found that 10% of
the final population of enriched cells were trisomic fetal
cells [13].
Increased proportions of fetal cells have been
detected in women with preeclampsia, which follows
historical observations by Schmorl [1] and Clayton et al
[48]. Holzgreve et al also noted a large increase in the
number of NRBCs (38 vs 7) in male-bearing pregnancies
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with preeclampsia [78]. Other factors that are likely
to influence the degree of transfer of fetal cells into
the maternal circulation are multiple gestation, feto-
maternal blood incompatibilities, and other maternal
complications, such as diabetes or bleeding. Another
issue is the possible influence of autoimmune disease,
such as scleroderma [79].
Various Methods to Enrich NRBCs from
Maternal Blood
For noninvasive diagnosis using fetal cells from the
maternal circulation, enrichment of NRBCs is essen-
tial. Methods include FACS, MACS, density gradient
centrifugation, charged flow separation, selective
erythrocyte lysis, and the lectin base method. Efficient
selection of NRBCs is essential for analysis of fetal
genetic abnormalities. Although a number of reports
describe successful enrichment of NRBCs, a preferred
method has yet to be established.
FACS and MACS
FACS and MACS were preferred methods for fetal
cell enrichment in the 1990s. Both technologies rely on
antigen–antibody recognition using NRBC-specific
monoclonal antibodies. In order to perform FACS, the
antibodies are first labeled with a fluorescent dye,
while they are labeled with magnetic beads for MACS.
As previously mentioned, Bianchi et al first used a
monoclonal antibody against CD71 to enrich NRBCs
[9]. They sorted CD71-positive cells from the blood
of pregnant women at 1,217 weeks’ gestation, after
which they performed PCR amplification of a Y-specific
sequence. They detected the Y-specific sequence in
75% of women bearing male fetuses. However, after
selection using the CD71 antibody, the purity of NRBCs
remained low. Subsequent to this, their group estab-
lished a new NRBC marker, a monoclonal antibody
against a-hemoglobin. This marker considerably im-
proved the purity of isolated NRBCs [80,81]. Ganshirt-
Ahlert et al then used MACS separation with magne-
tic beads bearing antibody against CD71 to successfully
identify fetal cells with chromosomal abnormalities
using FISH in blood samples from 15 pregnant women
bearing fetuses with chromosomal abnormalities [13,
82]. Some investigators have also used glycophorin A
for enrichment of NRBCs [83]. Purity can be further
enhanced by depletion of maternal cells and fetal
lymphocytes with anti-CD45 antibody prior to positive
selection for CD71-positive cells. Using this method,
approximately 20 fetal cells are obtained from a 20-mL
maternal blood sample [84]. However, even following
double MACS separation, the purity of NRBCs remains
low, and a prolonged interval is required for NRBC
detection. The advantages of using MACS include the
short time required for the procedure itself and its
relatively low cost. A disadvantage is that selection is
based on only one criterion, thus explaining the low
purity of NRBCs obtained.
In order to improve the recovery of NRBCs, Bianchi’s
group primarily examined samples collected after ter-
mination procedures, which are thought to increase the
number of NRBCs in maternal blood. They recovered
fetal NRBCs from maternal blood in all post-termination
samples [85–89]. We further observed an improvement
in the recovery of NRBCs by MACS negative selection
with CD45 prior to FACS separation using a-hemoglobin
antibody [81].
NIFTY Study
Based on the success of fetal NRBC detection using
FACS-FISH and/or MACS-FISH analysis, NRBCs were
thought to have potential for noninvasive fetal diagno-
sis. In the USA, to examine this possibility, a large-scale
multicenter study funded by the National Institutes of
Health, known as the National Institute of Child Health
and Human Development Fetal Cell Isolation Study
(NIFTY), was performed between 1995 and 1999 [17].
The purpose of the study was to assess the reliability
of noninvasive prenatal diagnosis of fetal aneuploidy
using NRBCs from maternal circulation. Subjects
thought to be at risk of carrying an aneuploid fetus (> 35
years of age), or with serum screening or sonographic
results suggestive of aneuploidy, about to undergo an
invasive diagnostic procedure, were selected. The re-
sults were compared with the karyotype obtained
following the invasive procedure as the gold standard.
Fetal cell detection had very low sensitivity in this study,
in which more than 2,700 maternal blood samples
were examined, ranging from 13% using FACS to 44%
using MACS. Thus, MACS separation yielded a better
recovery of fetal NRBCs than FACS separation [17]. Al-
though the purity of NRBCs was high following
FACS separation using a-hemoglobin antibody, fewer
NRBCs were recovered. In contrast, the greater number
of cells separated using MACS led to improved recovery
of NRBCs, despite an overall decrease in the proportion
of NRBCs to total cells collected. Thus, recovery of
NRBCs using MACS was slightly better than FACS.
However, fetal NRBCs were difficult to detect with
both methods. This is probably due to the extremely low
number and proportion of fetal NRBCs in maternal
blood. Consequently, this study concluded that the
utility of NRBC isolation using NRBC-specific antigens
is limited.
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Density gradient centrifugation
To separate NRBCs, removal of mature erythrocytes
is a very important initial step. Methods include bulk
separation, lysis, and various forms of selective cen-
trifugation. Since there is no report that NRBCs are
efficiently separated by cell lysis, more recent protocols
begin with some form of density gradient centrifuga-
tion intended to enrich a mononuclear cell-rich popu-
lation. In the early 1990s, a 1.077 g/mL density gradient
was primarily used. However, in 1993, Bhat el al showed
a 25-fold enhancement of NRBC isolation using a triple
density gradient [90] Using this protocol, fetal NRBCs
were successfully isolated from maternal blood of
aneuploid pregnancies in the second and third trimesters
[13].
In 1995, Takabayashi et al used discontinuous gra-
dients to enhance enrichment [15]. They placed a 2-mL
maternal venous blood sample on double density gra-
dients of 1.075 and 1.085 g/mL Percoll solution. Fol-
lowing centrifugation, cells with the targeted densi-
ties were placed on slides and stained with May-Giemsa
for morphologic NRBC identification. Takabayashi et
al identified a large proportion of NRBCs among the
nucleated cells obtained using this approach. An aver-
age of 4.1 NRBCs (122) were identified per sample
analyzed, from which fetal sex could be accurately de-
termined in 10 of 11 samples. NRBCs were detected as
early as 8 weeks’ gestation. Later, we evaluated the ef-
fects of various density gradients on recovery of NRBCs.
We used FACS separation based on a-hemoglobin and
subsequent FISH analysis [81]. The number of NRBCs
recovered using a gradient of 1.090 g/mL was three
times greater than with a gradient of 1.085 g/mL. More-
over, we recovered twice as many NRBCs using 1.119
g/mL than with 1.090 g/mL [80]. Voullarie et al examined
the density of NRBCs using a continuous Percoll density
gradient and revealed that most NRBCs have apparently
greater density than white blood cells [91]. Thus, since
NRBCs are more dense than white blood cells, it is
necessary to use greater density gradients to recover a
high yield of NRBCs. Some investigators prefer to use
Ficoll 1119 [92,93].
Other methods
Other methods used for enrichment of fetal cells in-
clude avidinbiotin columns, magnetic ferro-fluids, and
cell culturing. To enhance enrichment, some investi-
gators have sought more specific antibodies or bio-
chemical markers, while some have relied on chemical
assays for analysis, such as 2,3-biophosphoglycerate
(BPG) [52], carbonic anhydrase (CA) [60,94], and
thymidine kinase (TK) [95]. BPG is thought to identify
fetal hemoglobin by exposing the fetal heme-iron to
oxidization in a sequential peroxidase reaction, there-
by forming a colored substrate-associated complex.
Using a fluorescent thymidine analog, fetal cells can
be differentiated from adult cells based on TK enzyme
activity, which is virtually absent in adult cells. Fetal
NRBCs are also less susceptible to ammonium chloride
lysis than adult NRBCs since CA activity is fivefold less,
and acetozolamide permeability approximately 10-
fold greater. Other specific antibodies include HAE9
[96] and those developed by Genzyme (FB3-2, 2-6B/6,
and H3-3) [76]. The possibility of using an erythro-
poietin assay has also been explored [97]. However, at
the present time, most researchers still either use anti-
CD71 or anti-a-globin antibodies for enrichment of
NRBCs.
Other investigators have isolated very high num-
bers of NRBCs by charge flow separation [98,99],
which permits sorting of cells according to their
characteristic surface charge densities. Using this
method, several thousand NRBCs (average, 6,910) were
enriched from a 20-mL maternal venous blood sample
in one study, from which both fetal sex and ploidy could
be accurately examined. However, this result has not
been repeated.
Recent advances: the lectin-based method
A more recent study has used a galactose-specific lec-
tin for isolation of fetal NRBCs from maternal blood
[18]. The method is based on the observation that
erythroid precursor cells express large numbers of
galactose molecules on their cell surface, associated
with development and maturation of the cell. In this
study, the authors used soybean agglutinin as a
galactose-specific lectin to enrich high galactose-
expressing erythroid cells, from which they recovered
one to several hundred NRBCs (mean ± standard
deviation, 7.8 ± 8.5) from 2.3 mL of peripheral blood
from 96% of pregnant women between 6 and 27
weeks’ gestation. The isolated NRBCs were then ana-
lyzed using a Y chromosome-specific FISH probe in
eight cases carrying male fetuses, for which Y-signals
were detected in all eight cases, and more than half
of all NRBCs collected were of fetal origin. Subsequent
to this, Babochkina et al compared the success of this
method with MACS/CD71 separation, and revealed an
eightfold increase in NRBC recovery using this method
[100]. In an unpublished study of this method, we
evaluated how many NRBCs can be separated from the
blood of normal pregnant women in early gestation.
We detected NRBCs in all 32 cases examined (1–81
cells/sample). The median number of NRBCs detected
in normal pregnancy was 13 cells/6 mL of maternal
blood. In order to identify the NRBCs, we manually
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screened two slides per case, which was very labor
intensive. However, following enhancement with lectin,
most contaminant cells were non-nucleated erythrocytes.
The lectin method seems preferable to other methods,
such as MACS, since it is easy to use with automated
detection systems. Thus, the lectin method to enrich
NRBCs is considered the best method so far.
Autodetection
Since enrichment of NRBCs produces a low-purity
sample, the requirement for subsequent screening is
labor intensive. This has created interest in automated
detection systems, using laser-mediated scanning or
a charge-coupled device (CCD) with a video computer-
aided capture and dot-counting analysis system.
An approach pioneered by Zheng et al [101] and
Ferguson-Smith et al [102] has been to stain NRBCs
with fluorescence-conjugated anti-fetal hemoglobin
antibodies. Following detection of NRBCs, FISH ana-
lysis can be performed to diagnose fetal aneuploidies.
However, this system is still associated with difficulties,
since NRBCs must be morphologically identified, and
optimized staining conditions have yet to be determined.
Recently, a new system has been developed in which
cells enriched on the slide glass are stained, after which
the entire slide is examined by microscopy and the
findings read into a computer with a CCD camera, from
which NRBCs are identified based on their morphology.
This approach is becoming more feasible as the image-
processing capacity of computers improves.
DNA Analysis
When FISH and PCR, which are sensitive enough to
analyze single cells, became available in the late 1980s,
noninvasive prenatal diagnosis using maternal blood
became all the more possible. These two methods are
now used to analyze fetal cells. FISH can analyze fetal
gender and aneuploidies while PCR permits analysis of
mutations in single-gene disorders, as well as fetal
gender and rhesus blood type.
FISH analysis
Since Price et al reported the first case of fetal trisomy
21 diagnosed by isolation of NRBCs from maternal
blood [10], the FISH method has been used for non-
invasive prenatal diagnosis of fetal aneuploidies, as
well as fetal gender. In our own experiments, FISH
analysis of post-termination samples revealed that
NRBCs detected by positive staining for a-hemoglobin
were all fetal in origin [103]. However, when blood sam-
ples from normal pregnant women were examined,
most NRBCs were not suitable for FISH. We then
learned that 43% of fetal NRBCs collected from mater-
nal blood are apoptotic [87]. When NRBCs migrate
into maternal blood, they circulate under relatively
high oxygen tenion. As a result, they are more subject
to apoptosis [104] and the size of their nuclei is di-
minished [105]. This might be why FISH signals are not
detected in the nuclei. This problem warrants further
investigation.
PCR analysis
Through PCR amplification, we can evaluate fetal
DNA in NRBC-enriched samples. In fact, Bianchi et al
have reported the presence of a Y chromosome-specific
sequence in 75% of male-bearing maternal blood
samples [9]. However, this approach is not sufficiently
accurate for use in clinical practice. For diagnostic
purposes, individual NRBCs of fetal origin must be
examined, since half of NRBCs are maternal in origin.
Unfortunately, thus far, micromanipulation remains
the only method by which to isolate individual NRBCs
for analysis.
In 1995, Takabayashi et al pioneered a micromani-
pulation method by which to isolate NRBCs based on
morphology, accurately determining fetal sex in 10
of 11 cases [15]. We subsequently used this NRBC
separation method to retrieve individual NRBCs and
diagnose fetal single-gene disorders, such as Duchenne
muscular dystrophy and ornithine transcarbamylase
deficiency [16,106]. We demonstrated that PCR can be
performed on the genetic material obtained from a
single cell, a phenomenon made possible by whole
genome random primer extension preamplification
(PEP). As a result, we were able to determine whether
an NRBC was of fetal origin using differences in ZFX/ZFY
loci (to diagnose the gender of the cell), and also to
examine a particular gene of interest. Although this
was the first report of diagnosis of a fetal single-gene
disorder, over 100 cycles of PCR amplification, including
PEP and subsequent PCR of the target genes, were re-
quired to diagnose the origin of the cell and DNA alter-
ations leading to one or more single-gene disorders.
Thus, there are limitations to clinical use of this tech-
nology. Cheung et al have also prenatally diagnosed
hemoglobinopathies using multiple singly manipulated
fetal NRBCs identified by anti-fetal hemoglobin stain-
ing [107]. Using PCR, several cells should be retrieved
in order to circumvent the problem of allele dropout, a
phenomenon that frequently occurs when using single
or low template copies for PCR.
Thus, while PCR methods are highly sensitive, PCR
amplification errors at the single base sequence level
and allele dropouts may still occur.
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Conclusion
Fifteen years have passed since the first noninvasive
approaches to diagnosis of fetal genetic and chromo-
somal abnormalities using NRBCs in maternal blood
were developed. Although a number of noninvasive
approaches have been examined, all present limitations.
However, recent progress has increased the possibility
of noninvasive prenatal diagnosis.
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